Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Announces Pricing of Public Offering of Common Stock
MONROVIA, Calif. , March 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,300,000 shares of its common stock at a price to the public of $31.00 per share. All of the shares are being sold by Xencor .
View HTML
Toggle Summary Xencor, Inc. Announces Proposed Public Offering of Common Stock
MONROVIA, Calif. , March 19, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option
View HTML
Toggle Summary Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
-- Broadening Tumor Microenvironment (TME)-Targeting Bispecific Pipeline with XmAb®24306, Targeting IL-15/ILRa for Multiple Oncology Indications -- -- Expect to Initiate Phase 3 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD) in 2H18 -- -- Expect to Announce Initial Data from Phase 2 Trial of
View HTML
Toggle Summary Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors
MONROVIA, Calif. , Feb. 22, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been
View HTML
Toggle Summary Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018
MONROVIA, Calif. , Feb. 20, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release fourth quarter and
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Feb. 7, 2018 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Toggle Summary Xencor Announces 2018 Priorities and Expected Milestones
MONROVIA, Calif. , Jan. 5, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the company's 2018 priorities and
View HTML
Toggle Summary Xencor Appoints Richard Ranieri to Board of Directors
MONROVIA, Calif. , Dec. 19, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Richard Ranieri
View HTML
Toggle Summary Xencor Receives Milestone Payment from Amgen
MONROVIA, Calif. , Dec. 5, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company has earned a $10
View HTML
Toggle Summary Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Xencor to Host Analyst and Investor Event and Webcast on Saturday, November 11, 2017
View HTML
Xencor © Copyright 2018